Immune Checkpoint Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
206 Pages
January 2024
Region: Global
Fairfield Market Research
ID: 5934268

Immune checkpoints, pivotal proteins regulating the immune system, have emerged as key targets in cancer therapy. These proteins, when activated in cancer, suppress the body's anti-tumor immune responses, thwarting efforts to combat cancer cells. However, the study of immune checkpoint proteins has spurred the development of immune checkpoint inhibitors, a promising avenue in cancer treatment.

Pioneering Breakthroughs and Market Evolution

The introduction of immune checkpoint inhibitors like Ipilimumab (Yervoy) marked a significant milestone in cancer therapy. Initial successes in preclinical studies paved the way for the development of antibodies targeting the CTLA-4 and PD-1/PD-L1 pathways. Subsequent FDA approvals of immune checkpoint inhibitors including Yervoy, Bavencio, Tecentriq, Imfinzi, Opdivo, and Keytruda have reshaped the landscape of cancer treatment, offering new hope to patients worldwide.

Market Dynamics and Growth Projections

The global immune checkpoint inhibitors market is poised for robust growth, driven by the escalating prevalence of cancer and increased FDA approvals. However, challenges such as high R&D costs and regulatory price capping pose hurdles to market expansion. Despite these challenges, the market is forecasted to reach a valuation of US$150 Bn by 2031, with North America emerging as the dominant regional market.

Key Players and Future Prospects

Leading entities in the immune checkpoint inhibitors market, including AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer, and Sanofi, spearhead innovation in the field. Companies such as Novartis AG, Sanofi, and Incyte are positioned for future growth, with immune checkpoint inhibitor candidates in the pipeline awaiting regulatory approvals. Collaborations and agreements among manufacturers, exemplified by Bristol-Myers Squibb and Ono Pharmaceuticals, underscore a strategic approach aimed at expanding geographical reach and product indications.

Competitive Analysis

Key Companies functioning in the market are:

AstraZeneca Plc.

Bristol-Myers Squibb Co.
Roche Holding AG
Incyte Corporation
Merck & Co., Inc.
Merck KGaA
Sanofi
Novartis AG
Others.

Market Segmentation

Drug Class

PD-1
PD-L1
CTLA-4

Therapeutic Application

Lung Cancer
Melanoma
Squamous Cell Carcinoma
Urothelial Carcinoma
Blood cancer
Other Cancers

Distribution Channel

Hospital Pharmacies
Retail Pharmacies

Region

North America

U.S.
Canada

Latin America

Brazil
Mexico
Rest of Latin America

Europe

Germany
Russia
U.K.
France
Italy
Spain
Rest of Europe

Asia Pacific

India
China
Australia & New Zealand
ASEAN
Rest of APEJ

Japan

Middle East & Africa (MEA)

GCC Countries
South Africa
Rest of MEA

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Immune Checkpoint Inhibitors Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Immune Checkpoint Inhibitors Market Outlook, 2018 - 2031

3.1. Global Immune Checkpoint Inhibitors Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. PD-1
3.1.1.2. PD-L1
3.1.1.3. CTLA-4
3.2. Global Immune Checkpoint Inhibitors Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Lung Cancer
3.2.1.2. Melanoma
3.2.1.3. Squamous Cell Carcinoma
3.2.1.4. Urothelial Carcinoma
3.2.1.5. Blood cancer
3.2.1.6. Other Cancers
3.3. Global Immune Checkpoint Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.4. Global Immune Checkpoint Inhibitors Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa

4. North America Immune Checkpoint Inhibitors Market Outlook, 2018 - 2031

4.1. North America Immune Checkpoint Inhibitors Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. PD-1
4.1.1.2. PD-L1
4.1.1.3. CTLA-4
4.2. North America Immune Checkpoint Inhibitors Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Lung Cancer
4.2.1.2. Melanoma
4.2.1.3. Squamous Cell Carcinoma
4.2.1.4. Urothelial Carcinoma
4.2.1.5. Blood cancer
4.2.1.6. Other Cancers
4.3. North America Immune Checkpoint Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.4. North America Immune Checkpoint Inhibitors Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Immune Checkpoint Inhibitors Market Outlook, 2018 - 2031

5.1. Europe Immune Checkpoint Inhibitors Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. PD-1
5.1.1.2. PD-L1
5.1.1.3. CTLA-4
5.2. Europe Immune Checkpoint Inhibitors Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Lung Cancer
5.2.1.2. Melanoma
5.2.1.3. Squamous Cell Carcinoma
5.2.1.4. Urothelial Carcinoma
5.2.1.5. Blood cancer
5.2.1.6. Other Cancers
5.3. Europe Immune Checkpoint Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.4. Europe Immune Checkpoint Inhibitors Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Immune Checkpoint Inhibitors Market Outlook, 2018 - 2031

6.1. Asia Pacific Immune Checkpoint Inhibitors Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. PD-1
6.1.1.2. PD-L1
6.1.1.3. CTLA-4
6.2. Asia Pacific Immune Checkpoint Inhibitors Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Lung Cancer
6.2.1.2. Melanoma
6.2.1.3. Squamous Cell Carcinoma
6.2.1.4. Urothelial Carcinoma
6.2.1.5. Blood cancer
6.2.1.6. Other Cancers
6.3. Asia Pacific Immune Checkpoint Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.4. Asia Pacific Immune Checkpoint Inhibitors Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Immune Checkpoint Inhibitors Market Outlook, 2018 - 2031

7.1. Latin America Immune Checkpoint Inhibitors Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. PD-1
7.1.1.2. PD-L1
7.1.1.3. CTLA-4
7.2. Latin America Immune Checkpoint Inhibitors Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Lung Cancer
7.2.1.2. Melanoma
7.2.1.3. Squamous Cell Carcinoma
7.2.1.4. Urothelial Carcinoma
7.2.1.5. Blood cancer
7.2.1.6. Other Cancers
7.3. Latin America Immune Checkpoint Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.4. Latin America Immune Checkpoint Inhibitors Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Immune Checkpoint Inhibitors Market Outlook, 2018 - 2031

8.1. Middle East & Africa Immune Checkpoint Inhibitors Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. PD-1
8.1.1.2. PD-L1
8.1.1.3. CTLA-4
8.2. Middle East & Africa Immune Checkpoint Inhibitors Market Outlook, by Therapeutic Application, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Lung Cancer
8.2.1.2. Melanoma
8.2.1.3. Squamous Cell Carcinoma
8.2.1.4. Urothelial Carcinoma
8.2.1.5. Blood cancer
8.2.1.6. Other Cancers
8.3. Middle East & Africa Immune Checkpoint Inhibitors Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.4. Middle East & Africa Immune Checkpoint Inhibitors Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Immune Checkpoint Inhibitors Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Immune Checkpoint Inhibitors Market by Therapeutic Application, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Immune Checkpoint Inhibitors Market Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Drug Class vs Distribution Channel Heatmap
9.2. Manufacturer vs Distribution Channel Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. AstraZeneca Plc.
9.5.1.1. Company Overview
9.5.1.2. Drug Class Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Bristol-Myers Squibb Co.
9.5.2.1. Company Overview
9.5.2.2. Drug Class Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Roche Holding AG
9.5.3.1. Company Overview
9.5.3.2. Drug Class Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Incyte Corporation
9.5.4.1. Company Overview
9.5.4.2. Drug Class Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Merck KGaA
9.5.5.1. Company Overview
9.5.5.2. Drug Class Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Sanofi
9.5.6.1. Company Overview
9.5.6.2. Drug Class Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Novartis AG
9.5.7.1. Company Overview
9.5.7.2. Drug Class Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Regeneron Pharmaceuticals Inc
9.5.8.1. Company Overview
9.5.8.2. Drug Class Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. BeiGene, Ltd
9.5.9.1. Company Overview
9.5.9.2. Drug Class Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Shanghai Junshi Biosciences Co.
9.5.10.1. Company Overview
9.5.10.2. Drug Class Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. GlaxoSmithKline plc
9.5.11.1. Company Overview
9.5.11.2. Drug Class Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Innovent Biologics, Inc.
9.5.12.1. Company Overview
9.5.12.2. Drug Class Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AstraZeneca Plc.
Bristol-Myers Squibb Co.
Roche Holding AG
Incyte Corporation
Merck KGaA
Sanofi
Novartis AG
Regeneron Pharmaceuticals Inc
BeiGene, Ltd
Shanghai Junshi Biosciences Co.
GlaxoSmithKline plc
Innovent Biologics, Inc.

Methodology

LOADING...